Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 8Active not recruiting 3Terminated 2Not yet recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Thoracic 1Breast 1

Conditions

Prostatic Neoplasms 2Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Gemcitabine 13Specimen Handling 12Radiotherapy 12Androgen Antagonists 12Magnetic Resonance Spectroscopy 10Nivolumab 9pembrolizumab 8darolutamide 7Drug Therapy 7toripalimab 6Radiosurgery 6Docetaxel 6Cystectomy 6enzalutamide 5apalutamide 5Mitomycin 5Cisplatin 5Abiraterone Acetate 5disitamab vedotin 4cabozantinib 4abiraterone 4Pluvicto 4Ipilimumab 4Cyclophosphamide 4Biopsy 4Axitinib 4tislelizumab 3lenvatinib 3fludarabine 3cemiplimab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Glutamate Carboxypeptidase II × Genitourinary × Clear all
NCT06982222 2026-05-13

Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones

National Cancer Institute (NCI)

Phase 1 Not yet recruiting
24 enrolled
BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Prostatic Neoplasms

NCT06129851 2023-11-13

Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer

University of Kansas Medical Center

Phase 2 Not yet recruiting
90 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡